Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carbidopa + levodopa + naproxen
- Development stage
- Unknown
- Lead developer
- Northwestern University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
carbidopa + levodopa + naproxen is an investigational drug combination being evaluated by Northwestern University for its potential to mitigate brain functional adaptations and withdrawal symptoms in patients with chronic back pain and opioid use or misuse. This combination, often referred to in clinical studies as DA+NSAID, consists of the dopamine precursor levodopa, the DOPA decarboxylase inhibitor carbidopa, and the non-selective non-steroidal anti-inflammatory drug (NSAID) naproxen. The therapeutic rationale is to address the dysregulation of the brain's reward and dopaminergic systems caused by chronic opioid exposure while simultaneously managing pain through COX-1 and COX-2 inhibition. By providing a dopaminergic re-exposure without the use of opioids, the treatment aims to alleviate withdrawal-related brain changes and cognitive or emotional distress.
- Brand names
- Sinemet
- Other names
- DA+NSAIDCarbidopa-Levodopa + Naproxenopioids-Northwestern University-chronic back pain-opioid withdrawal
02
Targets
DDC (Aromatic L-amino acid decarboxylase)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DRD (Dopamine receptors)
Beyond the preview
Go deeper on carbidopa + levodopa + naproxen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carbidopa + levodopa + naproxen.